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Chapter 9
Modeling Risk Factors and Confounding Effects in Stroke
Barry McColl, David Howells, Nancy Rothwell, and Adam Denes
Abstract
 Most research to date has used experimental models in rodents which fail to mimic the underlying causes 
of stroke in patients or the primary confounding factors. Available data indicate that factors such as ath-
erosclerosis, hypertension, obesity, diabetes, age, and inflammation have a major influence on outcome. 
These findings suggest that we need to rethink the preclinical data that are required before selection of 
candidate interventions for clinical trials in stroke.
Key words: Atherosclerosis, Hypertension, Obesity, Diabetes, Age, Inflammation
Animals have been used successfully to study the underlying 
mechanisms of diverse diseases and to successfully develop new 
treatments. In many cases, the diseases in question are induced 
through a means which differs significantly from the clinical 
course and causes (e.g., implanted tumors in young and other-
wise healthy animals) mechanical or pharmacological induction of 
hypertension and cardiac disease, and pharmacological induction 
of diabetes. Some have used spontaneous mutations that result in 
the disease of interest (e.g., genetically obese animals), mutagen-
esis to cause a pathology (e.g., deafness), or specific genetic 
manipulation to induce disease (e.g., to cause mutations known 
to occur in Alzheimer’s). All of these have been very helpful in 
understanding disease pathology and in the development and 
testing of new medicines.
The situation in experimental studies on stroke is quite differ-
ent because the animal models we have used have revealed much 
knowledge of underlying pathological mechanisms, but have 
(with the notable exception of tPA) failed to deliver new medicines. 
1. Introduction
Ulrich Dirnagl (ed.), Rodent Models of Stroke, Neuromethods, vol. 47,
DOI 10.1007/978-1-60761-750-1_9, © Springer Science+Business Media, LLC 2010
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Thus, after many promising preclinical outcomes, we have numerous 
failed clinical trials in stroke. Many of these can be explained on 
the basis of inadequate preclinical data, poor clinical trial design, 
or a mismatch between the preclinical findings and the clinical 
studies; some failures remain inexplicable. This has caused a seri-
ous reanalysis of our experimental approaches to stroke, including 
the rigor of the experimental work and the relevance of com-
monly used methods (1–5).
To date, the vast majority of experimental studies on stroke 
have used young male rodents, with no confounding comorbidi-
ties, no parallel treatments, and no consequences of stroke. 
Furthermore, few studies have used approaches which mimic the 
clinical causes of stroke to induce cerebral ischemia. Indeed most 
have employed mechanical occlusion of a major artery (the mid-
dle cerebral artery); very few have used thrombus or hemorrhage 
or indeed studied animals with spontaneous stroke. A further fac-
tor which may have influenced the apparent discrepancy between 
rodent studies and clinical trials may be that unsurprisingly, stroke 
has been considered as a neurological disorder given that the 
clinical outcomes are neurological. Yet stroke is profoundly influ-
enced, and perhaps even caused, by systemic factors, including 
atherosclerosis, impaired cardiac function, systemic inflammation, 
and infection.
It is clearly not feasible, or probably helpful, to fully mimic all 
the common clinical factors associated with stroke simultaneously 
in animals. To develop aged, atherosclerotic animals, some of 
which have diabetes, many hypertension and obesity, some would 
be smokers, have a poor diet and others would have many other 
confounding factors and comorbidities, as well as exposure to a 
whole array of potential medicines, would make animal studies as 
complex and expensive as clinical trials. It would also make inter-
pretation of data near impossible. Animal research, in most coun-
tries, is further constrained by legislative and welfare considerations 
which quite rightly aim to limit suffering.
Thus, we focus here on the major confounding factors known 
to cause or exacerbate stroke i.e. hypertension, diabetes, obesity, 
infection, inflammation, atherosclerosis, and age and attempt to 
review available methods, their robustness and limitations, and 
available data.
Hypertension is the single most important modifiable risk factor 
(6–9), which increases stroke risk by 20–30% for a 10 mmHg 
increase in arterial blood pressure (8) and doubles the lifetime 
risk in individuals with blood pressure above 120/80 mmHg (10). 
2.  Hypertension
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Hypertension is evident in >50% of stroke patients (6–9). 
Improved diabetic control (11) and blood pressure reduction (12) 
both reduce stroke risk.
There are many animal paradigms of hypertension but only a 
few have been used to study stroke. To date, no stroke studies 
appear to have been undertaken in hypertensive transgenic rats 
expressing an extra copy of the renin gene (13) or in the New 
Zealand, Milan hypertensive or Lyon hypertensive rats (14–16). 
Hypertension and stroke have been induced in Cynomolgus 
monkeys by surgical coarctation in animals fed an atherogenic 
diet (17), but this would not seem to be a practical model for 
widespread use.
The most widely used hypertensive animals in stroke research 
are the spontaneous hypertensive rat (SHR) and the stroke-prone 
SHR (spSHR); the latter was derived by inbreeding of the off-
spring of SHRs that died of stroke. Over 80% of the spSHR pop-
ulation develops stroke, which is characterized by multifocal 
microvascular and spongy-cystic parenchymal lesions (18). Wistar 
Kyoto rats were the parent strain for both (19).
In spSHRs, a high salt diet precipitates renal injury, marked 
hypertension (>240 mmHg) and rapid onset of hemorrhagic 
stroke (20, 21), and ~70% of strokes are in the gray matter of the 
cortex (22). While the number of anastomotic connections 
between anterior and middle cerebral artery territories in the cor-
tex is similar to WKY rats, their luminal diameter is reduced (23–25), 
and capacity for vasodilation impaired (26–28).
SHR rats become hypertensive within 2–4 months of birth and 
attain a stable systolic blood pressure (~200 mmHg) by 6 months. 
Salt sensitivity is not a major component of their phenotype (29). 
The hypertension is accompanied by enlarged ventricles (30, 31), 
cerebral artery smooth muscle hypertrophy (32), increased 
macrophage activity (33), and reduced body and brain weight 
(30, 34, 35). Losses after thread occlusion of the MCA are sub-
stantially lower (36) than reported for the Dahl salt-sensitive rat.
In both the SHR and spSHR, focal cerebral ischemia leads to 
greater infarct volumes and behavioral deficits than in normoten-
sive controls and less variability (36–39). The reduced variability 
is also evident when submaximal infarcts are induced (Howells, 
personal observation) indicating that this, and the greater pro-
pensity to damage, results from reduced cortical collateral flow 
(40) imposed because of reduced luminal diameter (23–25), and 
reduced capacity for vasodilation (26–28). Reduced variability is 
not imposed by the absence of the posterior communicating 
arteries (41), the mechanism proposed for similar large infarcts, 
and small variability in the gerbil (42).
We were unable to find evidence of studies of most neuropro-
tective agents in hypertensive or diabetic animals. For six drugs that 
have been the subject of systematic review and meta-analysis, 
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only 10% of the publications identified included the modeling with 
high blood pressure or diabetes (43). Nicotinamide and FK506 
were substantially less effective in animals with diabetes or hyper-
tension (44, 45). NXY-059 was less effective in SHRs than in 
healthy animals (17.6% versus 47.8%; P < 0.001) (5) and tPA pro-
vided no benefit in SHRs but did increase the risk of hemorrhage 
(Sena and Howells, unpublished data). Hypothermia, however, was 
slightly more effective in SHR than in SD and Wister rats (43).
The impact of other neuroprotective agents in SHR rats has 
not been assessed systematically. Long-term control of hyperten-
sion with calcium or AT1 antagonists before MCAo appears to 
reduce infarction (46–49) while l-arginine has no effect when 
local CBF is unaltered (50) but reduces infarct volume when 
accompanied by increased cerebral blood flow (51). MK-801, the 
archetypal neuroprotectant has been reported to either have no 
effect (52) or to be less effective in hypertensive than in normo-
tensive controls (53).
Renovascular hypertension can be induced by clipping one 
renal artery (keeping the kidneys in place, 2 Kidneys, 1 Clip) to 
produce mild but relatively unstable hypertension (54) that nev-
ertheless exacerbates ischemic injury (55). Clipping both renal 
arteries in Sprague-Dawley rats leads to stable hypertension with 
spontaneous stroke characterized by a mixture of small infarcts 
with thrombotic occlusion and hemorrhagic lesions caused by 
bleeding from the arteriolar wall in 62% of the animals within 
40 weeks (56). Development of spontaneous T2-weighted MRI 
lesions in these models is tightly dependent upon blood pressure. 
After partial occlusion of both renal arteries, consistent brain 
lesions were seen only when blood pressure exceeded 276 mmHg 
(57). In agreement with these data is the observation that decom-
pressive craniectomy reduces MCAo induced mortality in reno-
vascular hypertensive rats by ~85% (58).
The Dahl salt-sensitive rat rapidly develops marked hyperten-
sion (~200 mmHg) when fed a high salt diet (8% NaCl), and this 
leads to blood–brain barrier disruption, stroke, and death (59, 
60). At lower salt concentrations (e.g., 1% NaCl), the same end is 
reached but the animals survive at least until ~5 months of age 
(61). Thread occlusion of the MCA after 5 weeks on a high salt 
diet leads to excessive death or hemorrhage at the MCA/ICA 
bifurcation. When the MCA was occluded for 120 min, 80% of 
the animals died or suffered hemorrhage within 24 h, 90 min 
occlusion still left 40% of the animals with hemorrhage (62).
Like the spSHR and renovascular models, rats made hyper-
tensive by treatment with mineralocorticoid receptor agonist 
deoxycorticosterone plus salt also suffer spontaneous strokes 
(63), but they are more readily protected against the effects of 
acute middle cerebral artery occlusion by antihypertensive treat-
ment with agents such as captopril than by spSHRs (64). 
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Spontaneous stroke and worsening of the effects of MCAo in 
these animals may be mediated by stiffening and narrowing of the 
middle cerebral artery (65).
Diabetes (type 1 & 2) or acute hyperglycemia is evident in 25% 
(66) and 40% (67) of stroke patients respectively, and both are 
associated with poor outcome (68–71).
Diabetes can be induced by selectively poisoning pancreatic 
b-cells with streptozotocin or Alloxan, by selective breeding in 
the nonobese diabetic (NOD) mouse, the BioBreeding (BB) rat, 
and occurs spontaneously in the Zucker diabetic fatty rat (72) and 
the Goto-Kakizaki rat (73). Specific defects in the db gene on 
mouse chromosome 4 and the fa gene on rat chromosome 5 both 
lead to leptin receptor defects (74, 75). Isolated hyperglycemia 
can be induced by infusion of glucose or dextrose (72).
Hyperglycemia accelerates and extends infarct development 
after MCAo in rats (76), cats (77), dogs (78), and rabbits (79). 
In cats (77), the three- to fourfold increase in infarct size due to 
hyperglycemia after permanent middle cerebral artery occlusion 
was associated with increased death due to edema upon reperfu-
sion. In monkeys, infusing glucose prior to cardiac arrest causes 
seizures and muscle twitching due to mild edema and necrosis of 
the cortex and basal ganglia (80). Some authors have reported that 
the effects of hyperglycemia on infarction are confined to the cere-
bral cortex (81), while others report that only very early and short-
term hyperglycemia may be needed to cause injury (82, 83).
Blood–brain barrier damage and edema (84–87) together 
with faster and larger infarct development after transient and per-
manent ischemic lesions (85) are also features of diabetes induced 
by chemical poisoning of pancreatic b-cells.
Where direct comparisons have been made between transient 
hyperglycemia and diabetes, the data are conflicting; some report 
similar degrees of exacerbation of postischemic injury (48) or that 
diabetes induces significantly more injury (88). Interestingly, when 
acute hyperglycemia lessens the impact of tPA therapy (83, 89), it 
has no effect on endogenous tPA expression, while a similar but 
persistent elevation of blood glucose (~15 mmol/L) in streptozo-
tocin-treated rats leads to a complete depletion of tPA protein and 
>6-fold loss of tPA mRNA expression (88).
In the BioBreeding (BB) rat, the effects of hyperglycemia on 
ischemia are gender and region specific. Males and females exhibit 
similar degrees of cortical injury, but subcortical infarction is larger 
in males (90). Similar observations have been made in the db/db 
mouse, where female diabetic mice became more hyperglycemic 
3. Diabetes/
Hyperglycemia
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and acidotic than the males even though they were more resistant 
to ischemic damage (91).
The recently described Goto-Kakizaki rat, which develops 
mild hyperglycemia at 6 weeks of age, is unusual in producing 
smaller infarcts after extended (3 h) MCAo (but high rates of 
subcortical hemorrhagic transformation) than do nondiabetic 
controls (73). While this has been interpreted as the result of 
diabetes-induced vascular remodeling (73), the infarcts look like 
the hypothalamic lesions produced when only hypothalamic per-
forating arteries are occluded (42) suggesting that reduced effec-
tiveness of thread occlusion might be a sensible alternative 
explanation. The observation that injury caused by compression-
induced cortical ischemia is greater in Goto-Kakizaki rats than in 
healthy Wistar controls (92) supports this hypothesis.
The impact of diabetes on efficacy of neuroprotection is not 
clear. Using insulin to control hyperglycemia has been reported to 
return neural injury to control levels and offer marked neuroprotec-
tion if blood glucose is reduced to below normal (93, 94). Similar 
protective effects on infarction were reported when insulin was used 
together with tPA in normoglycemic animals to treat thromboem-
bolic strokes. However, others report that tight glycemic control 
does not improve infarct size in male BB rats (90) and that, despite 
reduced infarct volumes, mortality was as high after insulin treat-
ment alone (47%) as it was when combined with tPA (38%) (95).
Growing evidence suggests that obesity predisposes to cardiovas-
cular disease including stroke (96–99). This association may be 
mediated indirectly via the susceptibility of obese individuals to 
established stroke risk factors, such as atherosclerosis, hyperten-
sion, hyperlipidemia, and insulin resistance/diabetes (100). In 
addition, there are considerable data indicating an independent 
association between obesity and stroke. Some studies have 
reported a graded elevation in stroke risk for each unit increase in 
body mass index (BMI) greater than 25 (97, 99) although others 
have not observed such a close correlation (101, 102). More 
recently, the validity of BMI as the optimal index for assessing the 
impact of obesity on cardiovascular disease has been questioned 
(103). Abdominal adiposity as measured by waist-to-hip ratio 
may provide better estimates of the health risks associated with 
obesity (104, 105). In support of this, a recent study demon-
strated a significant and graded association between the risk of 
stroke and transient ischemic attack and markers of abdominal 
obesity, including waist-to-hip ratio that was independent of 
hypertension and diabetes (103).
4.  Obesity
4.1. Association  
with Stroke Risk
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A huge number of animal models of obesity have been reported 
although the extent of characterization for each of these varies 
widely (106). In view of the predominance of rodent models in 
experimental stroke studies, obesity in mice and rats probably 
offers the greatest utility for experimental stroke researchers. 
Rodent models of obesity may arise through genetic mutation 
(spontaneous or targeted) or may be induced by some type of 
environmental stimulus e.g. high-fat diet (106). Genetic models 
may further be subdivided as monogenic and polygenic. 
Spontaneous mutants giving rise to monogenic rodent models of 
obesity are the most commonly used and have been characterized 
most extensively. Due to the diversity of models available, multi-
ple factors deserve consideration when choosing an obese model 
to incorporate in experimental stroke studies. These include 
strain, method of induction, sex-dependency, age of onset, sever-
ity and associated phenotypes. The following sections summarize 
some of the benefits and limitations/constraints of the most com-
monly used rodent obese models that are likely to be most worthy 
of consideration for experimental stroke studies. Readers are 
referred to these excellent resources for detailed accounts of these 
and other obesity models (106–108).
ob/ob Mice carry a spontaneous mutation in the Lep gene encod-
ing the leptin protein which is abundantly produced by adipo-
cytes (109). Mice homozygous for the Lepob mutation are 
deficient in leptin, which is an appetite-suppressing hormone. 
As a result, ob/ob mice (on Bl/6 background) are hyperphagic, 
and are first recognizable as obese at 4 weeks of age when fed a 
normal diet. Adult ob/ob mice may become three times the 
weight of wild-type controls. They are glucose intolerant, insulin 
resistant and hyperinsulinemic but are not hyperglycemic except 
during a short period in early adulthood (subsides by 12–16 weeks) 
(107, 108). Our own studies (McColl, Lawrence, unpublished) 
indicate a marked increase in hemorrhage on ob/ob mice exposed 
to MCAo.
db/db Mice carry a spontaneous mutation in the leptin receptor 
gene (Lepr), therefore there is a similar defect in the leptin axis as 
observed in ob/ob mice (110). Although obese, male mice 
homozygous for the Leprdb mutation (on Bl/6J background) are 
most commonly used as a model of diabetes (or obesity with dia-
betes) (111). These mice are also insulin resistant, hyperinsuline-
mic, and hyperlipidemic. Furthermore, and in contrast to ob/ob 
mice, they develop severe hyperglycemia and show symptoms 
consistent with overt diabetes (107).
The “fatty” Zucker rat has been extensively used in studies of obesity. 
Similar to the db/db mouse, the Zucker rat has a spontaneous 
4.2. Animal Models  
for the Study  
of Interactions 
Between Obesity  
and Stroke
4.2.1.  ob/ob Mice
4.2.2.  db/db Mice
4.2.3.  Zucker (fa/fa) Rats
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mutation in the leptin receptor (fa mutation) causing defective 
leptin signaling (112). Homozygous (fa/fa) mutants develop 
obesity and become hyperlipidemic and moderately insulin resis-
tant (112). In contrast to db/db mice, however, Zucker rats do 
not develop overt diabetes (107, 112).
Corpulent rats carry the spontaneously arising corpulent (cp) 
mutation, another mutation, affecting the leptin receptor render-
ing it dysfunctional. Rats homozygous for the mutation (cp/cp) 
develop obesity, insulin resistance, hyperinsulinemia, and hyper-
lipidemia but do not progress to type 2 diabetes (107). The origi-
nal hypertensive mutant strain (designated SHROB) was 
backcrossed to SHR, WKY, or LA strains, thus generating SHR/
N-cp (hypertensive), WKY/N-cp (normotensive control for 
SHR/N-cp) and LA/N-cp (normotensive) models (107). A fur-
ther strain designated JCR:LA-cp was developed as an outbred 
colony from early LA/N-cp breeding stock. Significantly, male 
JCR:LA-cp rats homozygous for the cp mutation develop sponta-
neous vascular pathology that includes atherosclerotic lesions 
similar to those observed in humans and ischemic lesions in the 
heart (113).
Several different types of dietary regimens have been used to 
induce obesity in rodents, including high-fat diets, high-energy 
diets (moderately high fat and high sugar), and palatable liquid 
diets. DIO has been characterized in both rats and mice, although 
there are strain-specific differences in susceptibility in both spe-
cies. Sprague-Dawley and Long Evans rats and C57Bl6/J mice 
are well established as susceptible strains, with males particularly 
predisposed (114, 115). Hyperphagia, obesity, insulin resistance, 
hyperinsulinemia, glucose intolerance, and hyperlipidemia are 
common features on adjusted diets, although the relative severity 
of each of these will depend on the exact composition of diet and 
strain susceptibility (116, 117). A commonly employed diet in 
male C57Bl6/J incorporates a 45% or 60% (by energy) fat com-
ponent, with controls being fed 10% fat. Mice are typically main-
tained on diets for up to 20 weeks. Modified diets such as these 
are available commercially (e.g., from Research Diets Inc.).
The animals described above illustrate some of the more com-
monly used rodent obesity models that may be applicable to 
incorporate in experimental stroke studies. The optimal model 
for any study will depend on multiple factors, including the exper-
imental hypothesis under testing, confounding factors, purchase 
and maintenance costs of animals/diets and stroke model used.
All the monogenic spontaneous mutant animals outlined 
above arise from deficiencies in the lepin/leptin receptor signaling 
axis. Leptin has a diverse array of actions in addition to its role 
4.2.4. Corpulent  
(cp/cp) Rats
4.2.5. Diet-Induced  
Obesity
4.3. General 
Considerations  
When Selecting 
Obesity Models  
for Experimental 
Stroke Studies
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in appetite regulation, including the effects on the immune and 
cardiovascular systems (83, 118). Accordingly, it could not be 
excluded that any effects on stroke responses in these models are 
because of leptin signaling insufficiency independent of obesity. 
To counter this, leptin replacement groups could be included 
although these are unlikely to fully restore the leptin axis to normal 
physiological conditions. This highlights a relative advantage of 
the diet-induced models. Furthermore, DIO is a more realistic 
model of the dietary component that is a key contributor to 
human obesity.
In humans, the vascular consequences commonly accompany 
obesity and metabolic syndrome that are of most relevance to 
stroke, since these are likely to mediate the link between metabolic 
disturbances and stroke susceptibility. However, with the exception 
of the JCR:LA-cp strain, all obese models are resistant to the devel-
opment of overt human-like vascular pathology (107). For this rea-
son, the JCR:LA-cp model that perhaps most closely resembles the 
metabolic syndrome associated with obesity most likely to present 
in stroke patients i.e. with downstream vascular abnormalities.
Hyperglycemia and diabetes are associated with poorer out-
come in stroke patients (see above); therefore, it may also be 
desirable to induce obesity without affecting glycemic status. This 
might enable the role of increased adiposity itself to be more eas-
ily delineated. This should be possible since some models (e.g., 
ob/ob mice after 12–16 weeks) are normoglycemic despite being 
markedly obese.
On a more practical note, it should be considered that obese 
animals, by definition, have large deposits of adipose tissue and 
that this has the potential to complicate the surgical induction of 
stroke (particularly filament models where access to the carotid 
vessels is a prerequisite). However, our own experience suggests 
that despite marginally extended surgery times, subcutaneous adi-
posity does not unduly affect success rates. This is also borne out 
by the recent studies that have emerged combining experimental 
obesity and stroke (119–122). All such studies have found that the 
severity of brain damage is markedly increased in obese rodents 
compared to corresponding wild-types (see below). This suggests 
that the basal severity of the stroke model may need to be titrated 
(e.g., by adjusting occlusion duration) to avoid excessive mortality 
and morbidity in the obese experimental group. Experimental 
stroke is commonly induced in 10–12 -week-old rodents. The 
rapid onset of obesity in the monogenic models enables similar 
aged animals to be used. In contrast, DIO involves long durations 
of feeding adjusted diet (perhaps up to 20 weeks); therefore, the 
age at which stroke can be induced in these animals is likely to be 
significantly older. Thus, the age and also the cost of long-term 
dietary modification and animal housing are important to consider. 
A further consideration is the difficulty in determining the doses of 
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any pharmacological intervention. Given the very different body 
weights, it is not possible to give interventions on a dose per unit 
body weight basis and highly lipophilic substances may be prefer-
entially taken up into adipose tissue.
These are just some of the many important factors to con-
sider when selecting an obesity model to incorporate in experi-
mental stroke studies. With good experimental planning and 
design and with particular attention to potentially confounding 
variables, most models are likely to enable a better understanding 
of the impact of obesity on stroke.
It is only in the last 2 years that studies investigating the impact of 
obesity on experimental stroke in rodents have emerged (119–122). 
All studies have found significantly increased ischemic brain damage 
in the obese group (see Table).
4.4. Overview  
of Experimental 
Obesity–Cerebral 
Ischemia Studies
Author Model
% Change in  
infarct References
Nagai et al. ob/ob
15 wk 42% high-fat diet
30% �
30% �
(119)
Terao et al. ob/ob 75% � (121)
Mayanagi et al. ob/ob 43% � (122)
Osmond et al. Zucker (fa/fa) 170% � (120)
The significance of atherosclerosis in the context of stroke risk is 
highlighted by the estimation that thromboembolism of athero-
sclerotic origin is the principal etiological factor in approximately 
50% of stroke patients (123). These statistics suggest that incor-
porating atherosclerosis in at least some preclinical stroke models 
should be a priority and should help to more accurately recapitu-
late important features of clinical stroke.
An extensive range of animal species have been used to study ath-
erosclerosis, including large animals such as nonhuman primates, 
pigs, rabbits, and, more recently, mice. The majority of experi-
mental stroke studies are performed in rodents therefore murine 
models of atherosclerosis are likely to offer the greatest utility for 
experimental stroke researchers.
The mouse is naturally resistant to spontaneous atherosclerosis, 
which may in part be the result of the HDL-dominant and 
5.  Atherosclerosis
5.1. Animal Models  
of Atherosclerosis
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antiatherogenic lipid profile in mice compared to the atherogenic 
LDL-dominant profile in humans (124). For this reason, feeding 
an atherogenic (commonly high-fat, high cholesterol) diet to 
genetically modified mice with enhanced susceptibility to athero-
sclerosis forms the basis of most currently used atherosclerosis 
protocols. A variety of diets have been described and the reader is 
referred to these excellent articles for more detailed information 
(124, 125).
Most wild-type mice are resistant to atherosclerosis when fed a 
conventional rodent chow diet; therefore, aggressive dietary 
manipulation is necessary to induce lesion formation. When fed a 
high-fat (30%), high cholesterol (5%), cholate-containing (2%) 
diet, or the “Paigen” diet (15% fat, 1.5% cholesterol, 0.5% cholate), 
C57Bl/6J mice develop small aortic lesions resembling the fatty 
streaks in humans by 4–5 months of age (124, 125). However, the 
lesions rarely progress beyond the early foam cell/fatty streak stage 
which represents the major limitation of these models.
In order to induce advanced atherosclerosis in mice, it is neces-
sary to use genetically-modified, susceptible strains, most com-
monly in combination with dietary modification. The most 
frequently used and best characterized strains are the apolipo-
protein E (apoE)−/− and low density lipoprotein receptor 
(LDLR)−/− mice. ApoE is a glycoprotein synthesized in many 
tissues and at highest levels in the liver and brain. It is a struc-
tural component of lipoprotein particles and acts as a ligand for 
receptors such as LDLR that mediate cellular internalization of 
apoE-containing particles (126). ApoE−/− mice when fed a chow 
diet are hypercholesterolemic and significantly have human-like 
lipoprotein profiles (i.e. low HDL) (127, 128). These mice 
develop lesions throughout the macrovasculature (but not in 
cerebral vessels) that progress to advanced plaques with a well-
defined fibrous cap consisting of smooth muscle cells, extracel-
lular matrix and foam cells (124). Feeding a Paigen diet or the 
more physiological “Western” diet (21% fat, 0.15% choles-
terol, cholate-free) accelerates the development of lesions at all 
stages (129).
LDLR is the principal receptor mediating the uptake of LDL via 
binding of its major ligand apoB (130). LDLR−/− mice develop 
more modest lipid abnormalities relative to apoE−/− mice, and 
therefore are much more resistant to atherosclerosis on a low-fat 
chow diet. However, when fed the Paigen or Western diets, 
LDLR−/− can develop intermediate-advanced lesions affecting 
multiple parts of the vasculature after 2–3 months (125).
5.1.1.  C57Bl/6J
5.1.2.  ApoE−/− Mice
5.1.3.  LDLR−/−
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In view of the various models of atherosclerosis available, several 
factors are likely to be worthy of consideration when selecting a 
model to incorporate in experimental stroke studies. The simi-
larity of the model to the human condition is of prime concern. 
In the context of atherosclerosis, the composition of the vascu-
lar lesions and the lipid profile are particularly important issues. 
As described above, the vascular pathology and lipid profiles 
observed in apoE−/− and LDLR−/− mice fed modified diets most 
closely reflect the human disease. Another advantage of these 
models is that the progression to advanced lesions progresses 
fairly rapidly, thereby reducing the duration of experiments and 
associated costs in maintenance. However, the use of geneti-
cally-modified mice in combination with dietary modification 
also introduces potentially confounding (124) variables. For 
example, there is evidence that the diets themselves may be 
proinflammatory and thus it may be difficult to distinguish 
between effects caused by atherosclerosis itself rather than 
diet alone. Analogous to this, genetic deficiency in apoE or 
LDLR may have important consequences independent of the 
induction of atherosclerosis. Notably, apoE has a number of 
important activities in the CNS, including homeostatic lipid 
transport (131). In addition, apoE has several neuroprotective 
and neuroregenerative features (131). For example, the extent 
of brain damage is significantly greater in apoE−/− mice (on reg-
ular chow diet) after a variety of acute brain injuries, including 
focal and global cerebral ischemia (131). Anti-inflammatory, 
antioxidant, and antiexcitotoxic properties have all been 
described for apoE in the brain (132). Although LDLR is a 
major receptor for apoE in peripheral tissues, this is not the case 
in the brain, where receptors such as LDLR-like protein (LRP) 
and apoE receptor 2 (apoER2) are the predominant transducers 
of apoE signaling (133). The use of LDLR−/− mice may there-
fore avoid some of the complications associated with apoE−/− 
mice since CNS apoE signaling pathways may be less severely 
compromised. Regardless, potential complications in interpret-
ing results from studies combining genetic and/or dietary models 
of atherosclerosis with experimental stroke will require the 
inclusion of multiple strain and diet control groups. If these are 
adequate, then it should be possible to extract meaningful con-
clusions from such studies. Aside from these design issues, an 
important practical consideration relates to the potential disruption 
of atherosclerotic lesions if stroke is induced by filament advance-
ment along the internal carotid artery. Although a full character-
ization of vascular pathology in the carotid and intracranial 
arteries is lacking, it is conceivable that filament advancement could 
dislodge atheromatous material, thus generating emboli-like 
particles which could complicate occlusion uniformity.
5.2. General 
Considerations  
When Choosing 
Atherosclerosis Models 
for Experimental 
Stroke Studies
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Since the incidence of stroke is higher in the elderly population 
compared to young people, it may be tempting to hypothesize 
that aging per se could facilitate stroke occurrence and/or impair 
outcome. It is, however, very difficult to separate the effect of age 
itself from many of its frequent peripheral or central comorbidities 
such as obesity, diabetes, hypertension, arteriosclerosis, or the 
presence of microhemorrhages and senile plaques in the brain. 
The use of aged animals (especially rodents) in experimental models 
of stroke may not perfectly reflect the human situation due to life 
span, strain and gender differences, and many other confounding 
factors. Nevertheless, several data have indicated similar effects of 
aging regarding infarct size, maturation, vascular and neuronal 
damage between patients and experimental animals.
It is known that in humans, cerebral blood vessels undergo 
profound changes with aging, including reduced capillary density 
and the formation of thickened and fibrotic basement membranes. 
Endothelial cells exhibit a reduced number of mitochondria, and 
in pericytes (which normally replace smooth muscle cells) degen-
erative processes are seen. In the aging human cortex, microhem-
orrhages become frequent, identified by their content of hem, red 
blood cells, collagen and clotting factors, and their spatial rela-
tionship to capillaries (134, 135). Similarly, vascular density, arte-
riole–arteriole anastomoses and basal blood flow decreases with 
age in rats (136), and structural changes are seen in basal lamina 
and endothelial cells (137).
Experimental stroke in rats generally (although not uniformly) 
reveals many factors which are altered in aged animals. In aged rats, 
increased mortality rate, but similar recovery and infarct volume 
were found (138). Another study showed that aged rats suffer 
larger infarctions, reduced functional recovery and increased BBB 
disruption that precede observable neuronal injury (139). Aging 
has been shown to reduce hypoxia-induced microvascular growth 
in the rodent hippocampus (140). Basal neurogenesis is impaired 
in the subgranular and subventricular zones of aged animals, 
although the magnitude of striatal neurogenesis after stroke is simi-
lar in young and old animals (141). Spontaneously hypertensive rat 
(SHR) models revealed larger infarcts in aged (18–22 months old) 
animals after photothrombotic distal MCAo compared to adults 
(142), and ischemic neuronal damage in the hippocampus and 
striatum was produced by 20 min of transient global ischemia in 
aged but not in adult rats (143).
In a recent report, stroke damage was found to increase 
with aging in female mice, whereas male mice had decreased 
damage after MCAo, which correlated with blood–brain barrier 
6.  Aging
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permeability changes. Interestingly, edema formation was less 
profound in aging mice, independent of sex and extent of his-
tologic damage (144).
These examples may indicate that depending on the ischemic 
model used, species, strain and gender differences, the observable 
effect of aging can be largely different. This may require much 
more comprehensive studies in the future to understand the key 
elements of the process of aging on damage formation, inflamma-
tion, and recovery.
To satisfactorily model inflammation and infection as risk factors 
in experimental stroke, it is important to understand the initia-
tion, maintenance, and termination of both central and peripheral 
inflammatory changes, with special respect to their interactions in 
cerebral ischemia. These processes can occur simultaneously in 
stroke, but the root causes may have started decades before their 
consequences are observed in the clinical practice, hence this area 
of experimental research is fraught with confounding factors.
Inflammation is a highly complex and normally well-coordinated 
biological response of vascular tissues to harmful stimuli. Typically, in 
peripheral tissues, acute inflammation induced by pathogen invasion 
or tissue injury includes a sequence of events aimed at eliminating 
deleterious agents and helping wound healing processes. Several ele-
ments of this reaction contain partially stimulus-specific components 
(for example the activation of certain toll-like receptors, which can 
recognize given pathogen-associated patterns) and also many com-
mon features, such as dilation of local blood vessels, the activation, 
recruitment of leukocytes and release a wide range of active peptide 
and nonpeptide mediators in inflamed tissues. While uncontrolled or 
prolonged inflammation can be highly detrimental in the periphery, 
its consequences may even be more serious in the brain, where 
anti-inflammatory and reparative processes would never result in 
complete recovery because of the very limited replacement of dam-
aged neurons.
Many elements of cerebral ischemia-induced inflammatory 
changes in the brain are very similar to the general pattern of the 
peripheral inflammatory response. The early central inflammatory 
events include the production of reactive oxygen species (nitric 
oxide, superoxide) expression of proteolytic enzymes (MMP-9, 
MMP-2), proinflammatory cytokines (IL-1b, TNFa, IL-6), 
chemokines (CINC-1, KC, MCP-1, MIP-1a), and vascular adhe-
sion molecules (ICAM-1, P-selectin, l-selectin). Activation of 
resident glial cells (astroglia, microglia) and early infiltration of 
granulocytes followed by monocytes, macrophages, and other 
hematogenous cells is observed within hours to weeks after experi-
mental stroke (58, 115, 121, 145–148).
Inhibition of inflammation is protective in most experimental 
models of stroke.
6.1. Inflammation and 
Infection: Risk Factors 
and Disease 
Consequences
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Because central inflammatory processes in stroke are associated 
with the disruption of the BBB and the formation of the ischemic 
damage, it is not easy to decide whether these changes are conse-
quences of the cerebral ischemic event itself or indeed contribute 
to damage formation. This may be one of the reasons why stroke 
has long been considered as a neurological disorder and the 
potential effect of systemic factors was largely neglected. In line 
with this, several studies that showed neuroprotection after cere-
bral ischemia by inhibiting certain components of the inflamma-
tory response failed to convincingly demonstrate whether this 
effect was centrally or peripherally mediated. In fact, inhibition or 
deletion of proinflammatory cytokines (149, 150), chemokines 
(151, 152), chemokine receptors (153, 154), treatment with tet-
racycline derivatives (155), etc., have all been shown to be protec-
tive in experimental rodent models of focal cerebral ischemia. 
One can also ask why such a robust inflammatory response is ini-
tiated in response to cerebral ischemia if it is harmful to the organ-
ism. Does postischemic inflammation involve similar mechanisms 
and/or effects in the periphery and in the brain? Although several 
reports showed that oxidative stress and recruitment of inflamma-
tory cells are harmful mainly in stroke, superoxide-initiated 
inflammation and monocyte recruitment seem crucial for periph-
eral, flow- or ischemia mediated vascular remodeling (156, 157). 
May modest and well-controlled inflammation facilitate processes 
of repair? For example, inhibition of matrix metalloproteinases in 
several rat or mouse MCAo models reduced damage size, brain 
edema formation, neuronal apoptosis (136, 158, 159), but facili-
tated cell death in intracerebral hemorrhage (160) or inhibited 
neuronal progenitor cell migration after photothrombotic isch-
emia in mouse (161). These examples indicate that the develop-
ment of more appropriate animal models, tissue- and cell-specific 
deletion, inhibition or overexpression of inflammatory mediators 
will be essential for a deeper understanding of underlying inflam-
matory mechanisms in stroke.
Inflammatory processes may differ between species and strains 
because of the differences in peripheral leukocyte populations, 
cerebral vasculature, size of the brain, kinetics of aging, etc.; 
therefore, in the future it may be advantageous to study cerebral 
ischemia more frequently in large mammals such as sheep (162) 
or swine (163). However, the availability and cost of animals may 
limit the number of these kinds of experiments.
Inflammation is elicited as a defense mechanism against infectious 
agents but is not necessarily caused by infection. The co-occur-
rence of these factors and the large overlap between the expres-
sion of infection-induced and ischemia-induced mediators create 
many confounding effects in clinical practice and in experimental 
stroke research. Pre-existing infection or systemic inflammation 
6.2. Systemic 
Inflammation and 
Infection: The Need  
for Appropriate 
Experimental Models
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may induce and is very likely to affect cerebral ischemia and 
relevant experimental models are crucial to understand the under-
lying mechanisms. In patients, acute- and chronic infection can 
be a trigger of stroke, and preceding infection worsens stroke 
outcome. Furthermore, poststroke infections affect clinical out-
come (164). Respiratory- and urinary tract infections are the 
most common types of infection preceding stroke after adjust-
ment for age and conventional vascular risk factors (165, 166).
To date, the effect of systemic inflammation and infection on 
experimental cerebral ischemia has been largely ignored in experi-
mental research. Similarly, the effect of cerebral ischemia on the 
induction or modulation of peripheral inflammatory processes 
has also been overlooked. It is now established that cerebral isch-
emia itself induces a rapid, but often prolonged peripheral inflam-
matory response. The level of proinflammatory cytokines, such as 
IL-6, IFNg, and MCP-1, becomes elevated in the plasma within 
hours and may remain elevated for several days in stroke patients 
and for 1–3 days in animals with experimental stroke. This is 
accompanied by the induction of chemokines and chemokine 
receptors in peripheral organs; long-term elevation of acute phase 
proteins and white blood cell counts in the circulation (167, 168). 
It is reasonable to ask how these processes are mediated and what 
the consequences of the activation of the peripheral inflammatory 
response on central inflammatory changes in stroke are.
It is crucial to reveal the mechanisms of peripheral inflamma-
tory changes in ischemic damage formation and to understand 
how a pre-existing inflammatory event can modulate all these 
processes in different experimental models. For example, deple-
tion of neutrophils in the periphery showed that these cells are a 
major source of oxygen radicals during reperfusion after focal 
cerebral ischemia in the rat MCAo model (169). Systemic inflam-
matory stimulus induced by intraperitoneal lipopolysaccharide 
(LPS ) or IL-1b administration exacerbates brain damage via a 
neutrophil-dependent mechanism in a mouse MCAo (170) and 
alters the kinetics of cerebrovascular tight junction disruption 
through neutrophil-derived MMP-9 (171). Therefore, studies 
using young, healthy animals with no additional inflammatory 
diseases may underestimate the impact that systemic factors have 
on patients with multiple comorbidities.
Another aspect of the peripheral changes caused by cerebral 
ischemia is profound immunosuppression, both in patients and in 
experimental animals. These changes include splenic atrophy, 
reduced B- and T cell counts and proliferation, reduced proin-
flammatory protein expression by blood cells (168, 172, 173). 
The underlying mechanisms may be similar to those leading to 
systemic immunodepression after brain trauma (174). It is not 
surprising that stroke-associated pneumonia is an important inde-
pendent contributor to poor outcome in patients (175, 176). 
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Experimental rodent models have been established to reveal the 
potential mechanisms and to find therapeutic targets. In a mouse 
model of focal cerebral ischemia, extensive apoptotic loss of lym-
phocytes, and a shift from T helper cell (Th)1 to Th2 cytokine 
production were observed and animals developed spontaneous 
septicemia and pneumonia (177). Preventive antibacterial treat-
ment improved the general medical and neurological outcome 
(178). It seems, therefore, that several parameters have to be 
taken into consideration for the experimental design to model the 
clinical situation because the interaction between ischemic and 
immune processes seems highly complex.
Due to the large overlap between inflammatory changes 
induced by ischemia and infection, in complex experimental mod-
els it may be very difficult to interpret results and to dissect mecha-
nisms. Several chemokines and proinflammatory cytokines, which 
become activated after stroke in the brain or in the periphery (167, 
168) are expressed in response to viral (179) and systemic bacterial 
infections (180). In addition, pathogen detecting sensors such as 
toll-like receptors (TLRs), and NOD-like receptors, activated by 
viral- (179) or microbial-derived molecules (181), not only recog-
nize various self-ligands such as heat shock proteins (182) or extra-
cellular matrix components (159), but also function as endogenous 
damage sensors, becoming activated during neuroinflammation 
and stroke (183, 184) and play a role in the production of cytok-
ines such as interleukin-1 beta (179). In line with this, mice lack-
ing either functional TLR4 (185) or TLR2 (186) are less susceptible 
to transient focal cerebral ischemia and reperfusion damage. 
Unfortunately, only very few studies have been performed on 
gnotobiotic animals; continued research could give further insights 
to the potential effects of the endogenous flora.
Timing can be another confounding factor in modeling the 
effects of inflammation or infection in experimental stroke 
research. As discussed above, acute or chronic (systemic) inflam-
mation may worsen the outcome after stroke, but precondition-
ing with LPS or preactivation of TLRs may be protective through 
mechanisms similar to ischemic tolerance. These events are most 
likely mediated through the hyporesponsiveness or reprogram-
ming of TLR-mediated signaling (187, 188).
Inflammation is associated with most known comorbidities. 
Interestingly, many comorbidities associated with stroke (such as 
diabetes, atherosclerosis or obesity) involve inflammation. For 
example, adipose tissue is now recognized as an abundant source 
of inflammatory mediators, and obesity is now considered a state of 
chronic inflammation with significantly elevated systemic levels 
of various cytokines, including tumor necrosis factor-a and inter-
leukin-6. Inflammation is strongly implicated in the development 
and/or progression of insulin resistance/diabetes, hypertension, 
and vascular disease-themselves key factors increasing stroke 
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susceptibility in obese individuals (189–191). Markers indicative 
of an increased prothrombotic tendency (e.g., increased levels of 
von Willebrand factor, plasminogen activator inhibitor-1) are also 
evident in obese individuals (191, 192). Inflammatory mediators 
such as TNF-a promote procoagulatory mechanisms and inhibit 
antithrombotic mediators (193), suggesting that increased inflam-
mation in obesity could cause a shift from anti- to prothrombotic 
status, thus favoring the development of a “stroke-prone” state. 
Similarly, atherosclerosis is a chronic inflammatory disorder that 
primarily affects large and medium-sized arteries at sites of dis-
turbed blood flow (194). Atherosclerotic lesions consist of 
endothelial cells, vascular smooth cells, and various immune cells, 
including T lymphocytes and monocytes and macrophages (195). 
These cells, in concert with a diverse array of soluble inflammatory 
mediators, modified lipids and proteases drive the progression of 
plaques from a relatively benign to highly unstable state prone to 
rupture. Plaque instability and rupture trigger thrombosis and 
intravascular occlusion, leading to stroke. The contribution of 
inflammatory mediators to the initiation or progression of these 
common comorbid conditions affecting stroke patients suggests 
that inflammation is a more important contributor to the inci-
dence and consequences of stroke in clinical reality than it is in 
experiments undertaken to date. It will be important to determine 
how a pre-existing inflammatory state resulting from acute (e.g., 
infection) or chronic (e.g., atherosclerosis) inflammatory condi-
tions modifies the peripheral and central inflammatory processes 
when an ischemic event occurs. Indeed, there is recent experimen-
tal evidence that peripheral inflammatory stimuli markedly alter 
the magnitude and kinetics of the peripheral and neurovascular 
inflammatory responses to experimental stroke (170, 171).
Beyond providing potential mechanisms for the interaction 
of systemic infections with stroke, these examples also highlight 
some of the technical considerations and difficulties involved in 
experimental models. As peripheral inflammation may modify the 
expression of inflammatory mediators in the inflamed CNS, cere-
bral ischemia may increase or blunt infection-induced changes in 
the periphery. The examination of multiple organs, evaluation in 
various time-points after ischemia and systems biology approaches 
can therefore be of great importance for achieving a more com-
plete understanding.
Our failure to adequately model the factors which cause a stroke 
and contribute to outcome in experimental studies may have been 
a significant factor in the failure of potentially promising 
7.  Conclusions
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therapeutic interventions. It is clear from laboratory studies that 
factors such as obesity, diabetes, atherosclerosis, and age have a 
profound effect on ischemic brain injury in rodents. But their 
inclusion in experimental studies is not without problems. Many 
of the methods used to induce such conditions have confounding 
effects. We rarely study spontaneous stroke caused by the factors 
which are known to predispose humans to stroke, and few studies 
have assessed the effects of multiple interventions, for example to 
mimic the cocktail of treatments applied to many patients. In spite 
of these difficulties, it seems clear that wider use of animal models 
with comorbidities is important for future research on stroke.
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